Drug Topics
JULY 14, 2025
Currently it’s going to be slowing to upper single digits through the forecast period, basically because 2 of the leading drugs, there's immune checkpoint inhibitors—nivolumab is the molecule—and pembrolizumab is Keytruda, 2 of those are going off patent in 2028 and 2029.
Pharmaceutical Technology
JULY 1, 2025
A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 8, 2025
There is also potential for an extra payout of up to $25m based on future Rezzayo regulatory milestones, with the milestone to be achieved by 30 June 2029. The cash component will be financed through existing funds and proceeds from CorMedix’s new $150m convertible debt financing arrangement with healthcare investors, including Deerfield.
Pharmacy Times
JULY 21, 2025
Completion Date (Estimated): December 2029 Neladalkib is a novel brain-penetrant ALK-selective inhibitor that was designed to overcome the limitations observed with currently available ALK inhibitors. 1,2 Currently, neladalkib is also being evaluated in the phase 2 portion of the ALKOVE-1 phase 1/2 clinical trial (NCT05384626).
Pharmaceutical Technology
JUNE 16, 2025
Find out more According to GlobalData’s Acute Lymphocytic Leukemia: Epidemiology Forecast to 2029 report, the number of diagnosed incident cases in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) is projected to increase from 25,636 in 2025 to 26,482 by 2029 at an annual growth rate of 1.16%.
Pharmaceutical Technology
JUNE 12, 2023
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. CB1 is predominantly found in the central and peripheral nervous system, whereas CB2 is primarily located in immune cells.
pharmaphorum
NOVEMBER 18, 2022
Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron , said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”.
Expert insights. Personalized for you.
Let's personalize your content